Trial
NCT00841035
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
OSI Pharmaceuticals
Condition
Pancreatic Cancer
Intervention
erlotinib
Why stopped
Sponsor stopped due to slow enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-19